Journal: Frontiers in Immunology
Article Title: Increased expression of CD36 and CD163 in clear cell renal cell carcinoma suggests an association between lipid transport and an “M2-like” macrophage phenotype
doi: 10.3389/fimmu.2026.1773666
Figure Lengend Snippet: Expression of CD68 and CD163 in ccRCC samples. (A) CD68 was assessed using immunohistochemistry. (B) Expression of CD68 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). (C) CD163 was assessed using immunohistochemistry. (D) Expression of CD163 was assessed using the available TCGA data (KIRC dataset). Tumors were grouped by the pathological tumor size (pT). Student’s t-test for two groups and one-way ANOVA for four groups; *p<0.05, **p<0.01, ***p<0.001,****p<0.0001. (E) Multiplex immunofluorescence imaging of ccRCC tumor tissues (representative of three patients) depicting CK (cytokeratin), CD163 and CD68 expression. White bar represents 200 μm (left) and 10 μm (right). (F) UMAP depicting clusters of single-cell data showing the expression of CD68 and CD163. Cell type annotations were adopted from the original publication . (G) Fraction of CD68+ cells co-expressing CD163 in RCC tumor tissue macrophage population. Positivity in scRNA-seq for CD68 and CD163 was defined from raw UMI counts as ≥1 UMI per gene (F) . (H) Flow cytometric analysis of CD45 on cells from central and peripheral ccRCC tumor tissue and adjacent kidney. (I) As in (H) , analysis of CD163 on CD68+ cells from central and peripheral ccRCC tumor tissue and adjacent kidney. Values were normalized to kidney controls. Representative histogram with geometric mean fluorescence intensities on the right. One-way ANOVA with Dunnett post-test comparing to kidney. *p<0.05, **p<0.01, ***p<0.001. (J) Data from (I) , tumor periphery, plotted as individual patients, depicting the portion of CD163+ and CD163neg cells.
Article Snippet: Reagents and antibodies used included FcR Blocking Reagent (Cat# 130-059-901), CD36 PE (Cat# 130-110-877), CD147 APC (Cat# 130-124-295), CD8a PE (Cat# 130-117-201), CD45 PE (Cat# 130-113-118), CD68 PE (Cat# 130-128-345), CD163 PE (Cat# 130-127-908), and pan-Cytokeratin APC (Cat# 130-123-091), all from Miltenyi Biotec.
Techniques: Expressing, Immunohistochemistry, Multiplex Assay, Immunofluorescence, Imaging, Single Cell, Fluorescence